Without a specific news catalyst, Incyte (INCY) has attracted attention after a period where the share price shows a one-month return of about negative 11% and a past three-month return around negative 9%.
See our latest analysis for Incyte.
At a share price of $90.33, the recent 1 month share price return of around an 11% decline continues the softer trend seen over 3 months and year to date, even though the 1 year total shareholder return of about 49% and 3 year total shareholder return of roughly 24% point to a stronger longer term picture.
If you want to see what else the market is pricing in for high growth themes, this is a good moment to scan 34 healthcare AI stocks
With the share price easing after a strong 1 year run and analysts’ average price target sitting higher at about $107.14, the key question now is whether Incyte is undervalued or whether the market already prices in future growth.
Most Popular Narrative: 9.8% Undervalued
With Incyte's fair value estimate at $100.10 compared to a last close of $90.33, the leading narrative frames the stock as modestly undervalued and heavily tied to pipeline execution.
The upcoming launches and label expansions of innovative therapies like Opzelura (ruxolitinib cream), povorcitinib, and Niktimvo in high-value indications such as atopic dermatitis, vitiligo, hidradenitis suppurativa (HS), and GVHD, along with a late-stage pipeline of targeted drugs, position Incyte to benefit from heightened demand for advanced immunology and oncology treatments as global populations age, which may support sustained revenue growth and future earnings.
Want to see what is built into that fair value? The narrative leans on specific revenue paths, margin shifts, and a tighter earnings multiple. The exact mix may surprise you.
Result: Fair Value of $100.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative can quickly be challenged if Jakafi concentration becomes an issue or if key late stage trials underdeliver against the high expectations that are now embedded.
Find out about the key risks to this Incyte narrative.
Another View: Cash Flows Point the Other Way
While the fair value narrative puts Incyte at about $100.10 per share, the SWS DCF model points to a future cash flow value closer to $50.79, with the current price of $90.33 sitting above that estimate. That gap raises a simple question: which story do you trust more, earnings or cash flows?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Incyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment clearly mixed across earnings, cash flows, risks, and opportunities, this is the moment to check the numbers yourself and decide where you stand. Start with 3 key rewards and 2 important warning signs.
Looking for more investment ideas?
If you stop with a single stock, you risk missing better fits for your goals, so take a few minutes to compare fresh ideas side by side.
- Spot potential bargains with robust fundamentals by checking the 62 high quality undervalued stocks.
- Prioritize resilience and peace of mind by scanning the 62 resilient stocks with low risk scores.
- Get an early look at underfollowed opportunities through the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com